
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="68F7E0A88095484300E0A800069A1382.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Pharmaceutical Statistics">
<meta name="citation_title" content="Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis">
<meta name="citation_author" content="Utkarsh Chauhan">
<meta name="citation_author_institution" content="Department of Medicine, University of Calgary, Calgary, Alberta, Canada">
<meta name="citation_author" content="Daylen Mackey">
<meta name="citation_author_institution" content="CW Trial Analytics, Edmonton, Alberta, Canada">
<meta name="citation_author" content="John R Mackey">
<meta name="citation_author_institution" content="Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada">
<meta name="citation_publication_date" content="2025 Apr 7">
<meta name="citation_volume" content="24">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="e70014">
<meta name="citation_doi" content="10.1002/pst.70014">
<meta name="citation_pmid" content="40194510">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/pdf/PST-24-0.pdf">
<meta name="description" content="Analyzing and effectively communicating the efficacy and toxicity of treatment is the fundamental basis of risk–benefit analysis (RBA). There is a need for more efficient and objective tools. We apply Chauhan Weighted Trajectory Analysis (CWTA) to ...">
<meta name="og:title" content="Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Analyzing and effectively communicating the efficacy and toxicity of treatment is the fundamental basis of risk–benefit analysis (RBA). There is a need for more efficient and objective tools. We apply Chauhan Weighted Trajectory Analysis (CWTA) to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11975450">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/pst.70014"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/PST-24-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11975450%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11975450/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11975450/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/pst.70014" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Pharm Stat</button></div>. 2025 Apr 7;24(3):e70014. doi: <a href="https://doi.org/10.1002/pst.70014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/pst.70014</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Pharm%20Stat%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pharm%20Stat%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Pharm%20Stat%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Pharm%20Stat%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chauhan%20U%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Utkarsh Chauhan</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Utkarsh Chauhan</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medicine, University of Calgary, Calgary, Alberta, Canada</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chauhan%20U%22%5BAuthor%5D" class="usa-link"><span class="name western">Utkarsh Chauhan</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mackey%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Daylen Mackey</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Daylen Mackey</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>CW Trial Analytics, Edmonton, Alberta, Canada</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mackey%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Daylen Mackey</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mackey%20JR%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">John R Mackey</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">John R Mackey</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mackey%20JR%22%5BAuthor%5D" class="usa-link"><span class="name western">John R Mackey</span></a>
</div>
</div>
<sup>3,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="pst70014-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Medicine, University of Calgary, Calgary, Alberta, Canada</div>
<div id="pst70014-aff-0002">
<sup>
<sup>2</sup>
</sup>CW Trial Analytics, Edmonton, Alberta, Canada</div>
<div id="pst70014-aff-0003">
<sup>
<sup>3</sup>
</sup>Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
John R. Mackey (<span>jmackey@ualberta.ca</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Mar 13; Received 2024 Sep 30; Accepted 2025 Mar 26; Issue date 2025 May-Jun.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>
<em>Pharmaceutical Statistics</em>© 2025 The Author(s). Pharmaceutical Statistics published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11975450  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40194510/" class="usa-link">40194510</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Analyzing and effectively communicating the efficacy and toxicity of treatment is the fundamental basis of risk–benefit analysis (RBA). There is a need for more efficient and objective tools. We apply Chauhan Weighted Trajectory Analysis (CWTA) to perform RBA with superior objectivity, power, and ease of communication. We used CWTA to perform 1000‐fold simulations of RCTs using ordinal endpoints that captured both treatment efficacy and treatment toxicity. RCTs were stochastically generated with 1:1 allocation at defined sample sizes and hazard ratios. We first studied the simplest case simulation of 3 levels each of toxicity and efficacy (a 3 × 3 matrix). We then simulated the general case of the advanced cancer trial, with efficacy graded by five RECIST 1.1 health statuses and toxicity graded by the six‐point CTCAE scale to create a 6 × 5 matrix. Finally, the 6 × 5 matrix model was applied to a real‐world dose escalation phase I trial in advanced cancer. Simulations in both the 3 × 3 simplest case matrix and the 6 × 5 advanced cancer matrix confirmed our hypothesis that drugs with both superior efficacy and toxicity profiles synergize for greater statistical power with CWTA RBA than either signal alone. The CWTA RBA 6 × 5 matrix meaningfully reduced sample size requirements over CWTA efficacy‐only analysis. Despite a small sample size, application of the matrix to each of the seven cohorts of the dose finding phase I clinical trial provided objective and statistically significant validation for the dose subjectively selected by the trialists. CWTA RBA, by incorporating both drug efficacy and the trajectory of drug toxicity, provides a single test statistic and summary plot that analyzes, visualizes, and effectively communicates the risk–benefit assessment of a clinical trial. CWTA RBA requires fewer patients than CWTA efficacy‐only analysis when the experimental drug is both more effective and less toxic. Our results show CWTA RBA has the potential to aid the objective and efficient assessment of new therapies throughout the drug development pathway. Furthermore, its distinct advantages over competing tests in visualizing and communicating risk–benefit will assist regulatory review, clinical adoption, and understanding of therapeutic risks and benefits by clinicians and patients alike.</p></section><section id="pst70014-sec-0001"><h2 class="pmc_sec_title">1. Introduction</h2>
<section id="pst70014-sec-0002"><h3 class="pmc_sec_title">1.1. Risk–Benefit Analysis (RBA) in Therapeutic Assessment</h3>
<p>RBA is the fundamental evaluation of a therapeutic intervention. In broad terms, RBA addresses the questions “Is this intervention more likely to help than harm? Is intervention A better than intervention B, when both efficacy and safety are considered?”</p>
<p>RBA is essential to the design, ethical review, and regulatory approval to start a study, where the potential benefits to patients are predicted to potentially outweigh the risks [<a href="#pst70014-bib-0001" class="usa-link" aria-describedby="pst70014-bib-0001">1</a>]. Subsequently, during the conduct of clinical trials, repeated RBAs are performed, often by involved investigators in early phase trials, or by independent data monitoring committees in phase II, III, and registrational studies, to ensure that the potential benefits of a clinical trial continue to outweigh the risks to participants. On completion of a trial, the risk–benefit assessment is the key metric on which the decision to advance through additional later stage trials, or seek regulatory approval, is based. Finally, the decisions of individual clinicians, insurance payers, and clinical guideline committees are predicated on the careful assessment of risk–benefit for individual patients and populations. In most cases, the RBA is a subjective assessment by experts informed of the totality of the safety and efficacy data, without the use of a formal statistical analytic tool that incorporates both safety and efficacy signals [<a href="#pst70014-bib-0002" class="usa-link" aria-describedby="pst70014-bib-0002">2</a>].</p>
<p>In the context of new drug development, RBAs are hampered by several practical problems. In early‐stage drug trials (first‐in‐human interventions, first‐in‐class drugs, and dose‐finding studies), the nature, severity, and duration of adverse events are largely unknown, as pre‐clinical models have only limited predictive ability for clinical toxicities [<a href="#pst70014-bib-0003" class="usa-link" aria-describedby="pst70014-bib-0003">3</a>, <a href="#pst70014-bib-0004" class="usa-link" aria-describedby="pst70014-bib-0004">4</a>]. Furthermore, patient benefit in early‐stage trials is generally not expected until effective doses are established, so formal risk–benefit calculations in this setting are difficult to pre‐specify. Typically, the aggregated experience of the patients in these studies is assessed subjectively, with particular emphasis on safety signals rather than efficacy. Finally, sample sizes are typically small and not amenable to standard statistical analytic techniques.</p>
<p>Even after key drug toxicities are identified and the recommended phase II doses are established, ongoing monitoring of risk–benefit still presents challenges in phase II, III, and phase IV settings. RBA is either formally or informally conducted by iterative reviews of patient outcomes during the clinical trial, typically presented as tables of most common and most severe adverse events, summary tables of efficacy signals, and lengthy and complex individual patient narratives [<a href="#pst70014-bib-0001" class="usa-link" aria-describedby="pst70014-bib-0001">1</a>]. These safety and efficacy data are complex to communicate, lack a unified statistical methodology that incorporates both, and are not readily displayed visually. In consequence, it is difficult to quickly grasp the timing, the reversibility, and the duration of toxicities from the standard presentation of clinical trial results while balancing them with the timing and magnitude of clinical efficacy experienced by patients on trial therapy. Furthermore, RBA is particularly complicated in the setting of a disease where the natural history of the illness varies in severity over time, independent of treatment effects, where the aggregated assessment of risk and benefit is more difficult than either assessment in isolation.</p></section><section id="pst70014-sec-0003"><h3 class="pmc_sec_title">1.2. Limitations of Kaplan–Meier Analysis for Efficacy and Toxicity Assessments</h3>
<p>The Kaplan–Meier analysis with logrank testing [<a href="#pst70014-bib-0005" class="usa-link" aria-describedby="pst70014-bib-0005">5</a>] is the gold‐standard method for the analysis of efficacy outcomes in most trials, including those in cancer patients. The KM estimator has many advantages: it is a nonparametric method, making it suitable for analyzing time‐to‐event data that may not follow a normal distribution, and it can handle censored data effectively, where some individuals may not experience the event of interest by the end of the study, ensuring that these individuals are appropriately accounted for in the analysis. The KM estimator is typically used in conjunction with the logrank test, which allows hypothesis testing to compare survival curves between different treatment groups in clinical trials. While the KM estimator provides a robust and widely accepted method for estimating survival functions from lifetime data, it does have several important limitations that reduce its utility. In particular, KM analyzes only a single time‐dependent endpoint for each trial participant and cannot provide a single analysis that incorporates the many key efficacy endpoints that may occur during a cancer patient's clinical course, including disease response, progression, and death. Furthermore, KM analysis can only model unidirectional outcomes (e.g., progression of disease) and cannot model the bi‐directional outcomes such as initial disease response, followed by later disease progression, and eventual death that represent the typical illness trajectory of patients with advanced cancer on clinical trials [<a href="#pst70014-bib-0006" class="usa-link" aria-describedby="pst70014-bib-0006">6</a>].</p></section><section id="pst70014-sec-0004"><h3 class="pmc_sec_title">1.3. Limitations of Adverse Event Tables for Safety Assessments</h3>
<p>The typical output of clinical trial safety assessments is tables of the highest grade of each CTCAE toxicity experienced by study subjects, where the trajectory of these side effects is not plotted for visual inspection, but must be derived from detailed reading of individual narrative reports for affected patients [<a href="#pst70014-bib-0001" class="usa-link" aria-describedby="pst70014-bib-0001">1</a>, <a href="#pst70014-bib-0002" class="usa-link" aria-describedby="pst70014-bib-0002">2</a>]. As such, the timing and the rapidity of onset, the reversibility and duration of maximal toxicity, and the rapidity of adverse event resolution are not typically detailed in clinical study reports or clinical trial publications.</p></section><section id="pst70014-sec-0005"><h3 class="pmc_sec_title">1.4. Rationale for Chauhan Weighted Trajectory Analysis (CWTA) in RBA
</h3>
<p>CWTA [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>] was specifically developed to address the limitations of KM analysis, while retaining a visual and test statistic output that would be easily interpreted by clinical and regulatory communities due to its similarity to KM analysis. A generalization of the KM methodology, CWTA has several advantages over traditional KM analysis. CWTA permits the assessment of outcomes defined by various ordinal grades or stages of clinical severity, which are common in medical settings but challenging to analyze using traditional methods like the KM estimator. Importantly, it facilitates continued analysis following changes in health state which may be bidirectional (disease recovery or exacerbation), providing a more comprehensive view of the trajectory of clinical outcomes [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>].</p>
<p>CWTA also retains the merits of KM analysis. It is a nonparametric method with the ability to censor patients who withdraw or are lost to follow‐up, ensuring robust analysis of clinical outcomes. CWTA, like KM, provides a graphical summary plot that visually depicts the trajectories of patients over time, making it easy to interpret and compare outcomes between different treatment arms. This is particularly important in the setting of clinical oncology, where oncologists have become accustomed to seeing a single plot for efficacy endpoints of clinical trials, in which the separation of the control and experimental curves conveys meaningful information as to the differential effects of treatment through time. Finally, CWTA introduces a weighted logrank test, a modification of the traditional logrank test, to assess the statistical significance of differences in trajectories between groups, providing a rigorous method for hypothesis testing that is also a familiar analog for clinicians and regulatory agents [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>].</p>
<p>Furthermore, CWTA is a more powerful analytic tool than KM analysis. We recently reported that in the setting of advanced cancer efficacy studies, by using all efficacy signals (CR, PR, SD, PD, and death), CWTA was markedly more powerful than KM analysis for the standard single endpoints of PFS or OS [<a href="#pst70014-bib-0008" class="usa-link" aria-describedby="pst70014-bib-0008">8</a>]. Sample size reductions ranged from 15% to 35%, and time to first efficacy signals were reduced by twofold to sixfold. Consequently, CWTA is particularly advantageous in deriving early informative efficacy signals in small sample size studies, populations of patients with rare diseases, and studies where enrollment capacity is limited.</p>
<p>We hypothesized that the risk–benefit analyses of many clinical trials are hampered by the lack of a single analytic tool that incorporates both efficacy and safety signals and conveys the aggregated signal in a visually intuitive, statistically tractable, and easily communicated manner. Due to the complexity and subjectivity of the risk–benefit assessment process throughout the drug development process, we sought and developed a tool that can simultaneously incorporate both benefit (efficacy) endpoints and risk (safety) endpoints in a single objective metric, display this visually, and conduct a formal statistical comparison of group outcomes. We developed and modeled this tool in the context of advanced cancer, using standard RECIST 1.1 criteria [<a href="#pst70014-bib-0009" class="usa-link" aria-describedby="pst70014-bib-0009">9</a>] for efficacy and CTCAE v5.0 criteria [<a href="#pst70014-bib-0010" class="usa-link" aria-describedby="pst70014-bib-0010">10</a>] for toxicity. For clinical validation with a real‐world trial dataset, we then applied the CWTA RBA methodology to an early‐stage clinical trial in advanced cancer by incorporating both comprehensive efficacy outcomes, together with detailed daily toxicity outcomes, to evaluate the clinical benefit of a novel therapy.</p></section><section id="pst70014-sec-0006"><h3 class="pmc_sec_title">1.5. Historical Approaches: Complexity at the Cost of Utility</h3>
<p>Previous attempts to generalize nonparametric tests such as Kaplan–Meier, including the use of weighted approaches, have had minimal impact on modern pharmaceutical trial design. Aalen generalized KM for counting processes by making strong assumptions about the influence of past history on the hazard of increasing state—leading to uncontrolled Type I error if these assumptions are not met [<a href="#pst70014-bib-0011" class="usa-link" aria-describedby="pst70014-bib-0011">11</a>]. Fleming and Harrington proposed a flexible method of weighted‐logrank tests to detect differences in survival distributions [<a href="#pst70014-bib-0012" class="usa-link" aria-describedby="pst70014-bib-0012">12</a>]. While their weighting function is robust to early treatment effects and crossing hazards, the performance of the test relies heavily on their chosen weighting function. This leads to frequent underperformance relative to the standard KM approach in their published simulations, and more importantly, complicates the interpretation of results when simulated parameters lend different statistical power to early, middle, or late survival differences. Nearly a decade later, Wei, Lin, and Weissfeld modeled marginal distributions for multivariate failure time analysis, again at the prohibitive cost of interpreting separate regression coefficients for each distribution [<a href="#pst70014-bib-0013" class="usa-link" aria-describedby="pst70014-bib-0013">13</a>]. Ordinal Generalized Estimation Equation (GEE) longitudinal analysis (Liang and Zeger, Lumley) provides a culmination of these efforts. CWTA not only provides more statistical power (see direct comparison to GEE in Chauhan, 2023) but provides a clear visualization of results that defines its clinical utility above these historical approaches [<a href="#pst70014-bib-0014" class="usa-link" aria-describedby="pst70014-bib-0014">14</a>, <a href="#pst70014-bib-0015" class="usa-link" aria-describedby="pst70014-bib-0015">15</a>].</p>
<p>There is a wide body of relevant literature on multistate modeling (MSM; Anderson and Keiding) including applications to cancer clinical trials (Le‐Rademacher [<a href="#pst70014-bib-0016" class="usa-link" aria-describedby="pst70014-bib-0016">16</a>, <a href="#pst70014-bib-0017" class="usa-link" aria-describedby="pst70014-bib-0017">17</a>]). Multistate modeling allows the examination of treatment effects on independent state transitions, which is critical to understanding the nuanced effect of drug and device interventions—a significant advantage over standard KM analysis. Although MSM techniques were introduced 40 years previously, they are rarely used in clinical practice, both due to their lack of summary significance tests and convoluted graphical representations—particularly in cases where treatment effects pull in different directions at sequential levels of morbidity. Ultimately, MSM is a complementary approach to both survival analysis and CWTA, where it can be used to extract hazard ratios for unique transitions or understand the time dependence of morbidity if not readily apparent from CWTA's single summary plot and <em>p</em>‐value.</p>
<p>The present manuscript on RBA in ordinal events using a simple efficacy‐toxicity matrix as outlined in the subsequent section has no direct historical comparator, but represents the logical extension of our previous work on CWTA for efficacy and safety endpoints. This approach retains the utility needed for biomedical research with relative simplicity in communication and interpretation of results required by a broad audience.</p></section></section><section id="pst70014-sec-0007"><h2 class="pmc_sec_title">2. Methods</h2>
<section id="pst70014-sec-0008"><h3 class="pmc_sec_title">2.1. CWTA</h3>
<p>For a complete description of CWTA, see Chauhan et al. [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>]. Below is a concise overview.</p>
<p>CWTA is a novel statistical method designed to evaluate clinical outcomes characterized by ordinal variables that can fluctuate over time. As a generalization of the Kaplan–Meier (KM) estimator, it remains a nonparametric test that provides the ability to censor patients that withdraw or are lost to follow‐up. As with KM, outcomes can be assessed using a summary plot that depicts all patients in serial time. The logrank test is modified to a “weighted” logrank test reliant on a multivariate hypergeometric distribution, but the mechanics of the Chi‐Squared test underlying are preserved.</p>
<p>In CWTA, an event is redefined as a change in an ordinal severity score (generally, a grade or stage of disease) that does not omit a patient from subsequent analysis. Both increases and decreases in the variable of interest are captured as events. Additionally, patients can enter CWTA at any starting stage. This redefinition allows clinical assessment of the overall trajectory of a group of patients, and graphically, the staircase plot can both descend and rise to capture dynamic clinical status. Events are a combination of polarity and magnitude of stage transition.</p>
<p>Plotted on the <em>y</em>‐axis is the weighted health status. The weighted health status at time point <em>j</em> is denoted by <em>U</em>
<sub>
<em>j</em>
</sub>, where <em>j</em> = 0, 1, … <em>z</em>. For each treatment arm, <em>U</em>
<sub>
<em>j</em>
</sub> has a maximum value of 1 (all patients have minimum disease burden, e.g., healthy cohort) and a minimum value of 0 (all patients have maximum disease burden, e.g., all patients died). Suppose a group of <em>n =</em> 100 patients is enrolled at time <em>j</em> = 0 (<em>n</em>
<sub>
<em>j</em>
</sub> 
<em>= n</em>
<sub>
<em>0</em>
</sub> = 100) with a range of disease severity from Grade 0 to 4 (<em>r</em> = 4). Each patient has a “weight” equal to this range, and thus the total group weight is <em>n0 * r</em> = 400. If all patients are enrolled in the trial with perfect health, <em>U</em>
<sub>
<em>j</em>
</sub> = <em>U</em>
<sub>0</sub> = 1. If all patients enrolled in the trial experience a transition from stage 0 to 1 in the first week of the trial, 100 points are lost, and the second plotted time point would equal 300/400 = 0.75. If 100 patients are subsequently lost to follow‐up in the second week but no fluctuations in disease occur, the third plotted time point remains 0.75. Importantly, the entire initial group weight remains as the denominator for fluctuations in the curve, not only surviving patients as depicted in KM, which depicts probability rather than overall disease burden.</p>
<p>The flexibility of plotting weighted health status facilitates a direct comparison of disease trajectory as a function of time and morbidity. Unlike KM, CWTA can demonstrate the transient nature of illness, account for successive exacerbations, and ultimately capture a wealth of patient data to increase trial power. This permits trial design with smaller sample sizes and expedites signals of efficacy as detailed in Chauhan et al. [<a href="#pst70014-bib-0008" class="usa-link" aria-describedby="pst70014-bib-0008">8</a>].</p></section><section id="pst70014-sec-0009"><h3 class="pmc_sec_title">2.2. 
CWTA for Risk–Benefit Analysis</h3>
<p>CWTA RBA analysis relies on the construction of a simple matrix with columns of increasing efficacy <strong>ε</strong> and rows of increasing toxicity <strong>θ</strong>. Thus, the score assigned to a given patient experiencing a given level of efficacy and toxicity is specified in the matrix element [<strong>ε</strong>, <strong>θ</strong>]. These matrices are constructed based on four rules:
</p>
<ol id="pst70014-list-0001" class="list" style="list-style-type:decimal">
<li id="pst70014-li-0001"><p>The element [0,0] represents maximal efficacy and minimum toxicity (a state of maximum health for any given subject);</p></li>
<li id="pst70014-li-0002"><div class="p">Nonfatal scores of efficacy and toxicity increase monotonically
<ol id="pst70014-list-0002" class="list" style="list-style-type:lower-alpha">
<li id="pst70014-li-0003"><div class="p">Increments can follow patterns such as (0, 1, 2, …) or (0, 2, 4…), as defined by the clinical context*.</div></li>
<li id="pst70014-li-0004"><div class="p">These define the zero‐indexed rows (efficacy) and columns (toxicity).</div></li>
</ol>
</div></li>
<li id="pst70014-li-0005"><div class="p">For nonfatal scores of efficacy and toxicity, matrix element [<strong>ε</strong>, <strong>θ</strong>] = [0, <strong>θ</strong>] + [<strong>ε</strong>, 0]
<ol id="pst70014-list-0003" class="list" style="list-style-type:lower-alpha"><li id="pst70014-li-0006"><div class="p">i.e. element [<a href="#pst70014-bib-0002" class="usa-link" aria-describedby="pst70014-bib-0002">2</a>, <a href="#pst70014-bib-0004" class="usa-link" aria-describedby="pst70014-bib-0004">4</a>] is the sum of [0, 4] and [2, 0]</div></li></ol>
</div></li>
<li id="pst70014-li-0007"><p>Fatal toxicity and efficacy (death from disease progression or treatment toxicity), independent of the preceding state, are always assigned an identical score <strong>
<em>F</em>
</strong>, which is 1 higher than the maximum value that can be reached by any nonfatal efficacy and toxicity combination**.</p></li>
</ol>
<p>*The key clinical context is the clinical relevance of progressive efficacy and toxicity score. A transition from stable to progressive disease likely represents more morbidity than a transition from mild to moderate treatment toxicity. The size of the increment is the <em>only</em> subjective component of this matrix, and it must be determined prospectively by the investigators.</p>
<p>**Rule 4 takes precedence over Rule 3 for fatal states.</p>
<p>To study CWTA risk–benefit analysis, we created simulation models at two levels of complexity.</p>
<p>For the first model, a 3 × 3 matrix outlined in Tables <a href="#pst70014-tbl-0001" class="usa-link">1</a> and <a href="#pst70014-tbl-0002" class="usa-link">2</a>, we defined three efficacy states (healthy, sick, dead) and three safety states (toxicity none, toxicity some, lethal toxicity). The goal of the first model is to test the hypothesis that a drug that both reduces morbidity and has lower toxicity compared to a drug with only one (or neither) of these attributes will demonstrate greater statistical power in CWTA RBA analysis.</p>
<section class="tw xbox font-sm" id="pst70014-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Ordinal efficacy and safety variables used for the simple 3 × 3 model.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Health status</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Ordinal value</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Type</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Healthy</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sick</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dead from disease</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">Irreversible and absorptive</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nontoxic</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Toxic</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Poisoned</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">Irreversible and absorptive</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pst70014-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section class="tw xbox font-sm" id="pst70014-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Ordinal efficacy and safety matrix used for the 3 × 3 simplest case simulations.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Healthy</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Sick</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Fatal disease</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nontoxic</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Toxic</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fatal toxicity</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pst70014-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Our second model was a 6 × 5 matrix described in Tables <a href="#pst70014-tbl-0003" class="usa-link">3</a> and <a href="#pst70014-tbl-0004" class="usa-link">4</a>. 6 rows correspond to tiers of toxicity based on CTCAE v5.0 [<a href="#pst70014-bib-0010" class="usa-link" aria-describedby="pst70014-bib-0010">10</a>], which range from no toxicity to fatal toxicity; 5 columns correspond to tiers of efficacy including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), and death defined as per RECIST 1.1 criteria [<a href="#pst70014-bib-0009" class="usa-link" aria-describedby="pst70014-bib-0009">9</a>]. The goal of the second model is to (i) demonstrate how clinical grading systems can easily be integrated in CWTA RBA and (ii) test the intuition established in the first model that combined efficacy and toxicity analysis offers greater statistical power compared to efficacy analysis alone. The same matrix is later applied to the real world advanced cancer validation study.</p>
<section class="tw xbox font-sm" id="pst70014-tbl-0003"><h4 class="obj_head">TABLE 3.</h4>
<div class="caption p"><p>Ordinal efficacy variables used for the advanced cancer analysis based on RECIST 1.1 criteria.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Health status</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Ordinal value</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Type</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Tumor in complete response (CR)</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Tumor in partial response (PR)</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Stable disease (at baseline; SD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">Reversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Progressive disease (PD)</td>
<td align="center" valign="top" rowspan="1" colspan="1">6</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nonreversible</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Death (from cancer)</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nonreversible/absorptive</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pst70014-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section class="tw xbox font-sm" id="pst70014-tbl-0004"><h4 class="obj_head">TABLE 4.</h4>
<div class="caption p"><p>Ordinal efficacy and safety matrix used for the advanced cancer analysis.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="2" colspan="2" valign="bottom"></th>
<th align="center" colspan="5" valign="bottom" rowspan="1">Efficacy</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="center" valign="bottom" rowspan="1" colspan="1">CR</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">PR</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">SD</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">PD</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Death</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="6" valign="top" colspan="1">Toxicity</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">6</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">7</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">6</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">7</td>
<td align="center" valign="top" rowspan="1" colspan="1">9</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">6</td>
<td align="center" valign="top" rowspan="1" colspan="1">8</td>
<td align="center" valign="top" rowspan="1" colspan="1">10</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
<td align="center" valign="top" rowspan="1" colspan="1">11</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pst70014-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="pst70014-note-0001"><p>
<em>Note:</em> All toxicity states are potentially reversible except death.</p></div></div></section></section><section id="pst70014-sec-0010"><h3 class="pmc_sec_title">2.3. Simulation Design</h3>
<p>The simulation studies were generated using Python 3.8 [<a href="#pst70014-bib-0018" class="usa-link" aria-describedby="pst70014-bib-0018">18</a>]. Study simulations were stochastic processes in which randomly generated numbers are programmed to mirror fluctuating disease responses to chemotherapy cycles with weekly measurements of treatment efficacy and toxicity. Patients could only change one efficacy level per month but could transition weekly to any toxicity level; higher likelihoods were assigned for transitions to more proximal scores. A Markov assumption is followed: future risk is dependent only on the current state and entirely independent of event history. Event probabilities were modified between groups as defined by a hazard ratio (HR) which is constant in time. We did not model patient dropout. We performed 1000‐fold simulations of chemotherapy RCTs at defined sample size (SS) allocated 1:1 to control or intervention and run for a defined number of weeks and used CWTA (weighted logrank test) to determine statistical significance.</p>
<p>As the trial is simulated, each control participant has a baseline risk of disease exacerbation (an efficacy event) or experiencing treatment toxicity (a toxicity event). These baseline rates are assigned through an iterative process to achieve cumulative event rates reflective of the studied cohort by referencing historical trial data or population level databases such as SEER [<a href="#pst70014-bib-0019" class="usa-link" aria-describedby="pst70014-bib-0019">19</a>]. A hazard ratio—the relative risk of an event occurring at any point in time during a study between two groups—is assigned as a fixed value at the beginning of each simulation to modulate the intervention group's event probabilities. For example, if a simulation is iterated weekly at a hazard ratio of 0.5, a control participant has a disease exacerbation probability of 10% at the end of each week, whereas an intervention participant has a transition probability of 5%. These hazard ratios apply inversely to disease recovery. Importantly, combined efficacy and toxicity analysis does not have a “summary” hazard ratio at the end of the trial—by definition, the proportional hazards assumption on a complete RBA dataset is violated, so no analogous approach to Cox Proportional modeling is appropriate.</p></section><section id="pst70014-sec-0011"><h3 class="pmc_sec_title">2.4. Simplest Case Simulation—3 Toxicity × 3 Efficacy Matrix</h3>
<p>We first modeled the simplest possible state for combined efficacy and toxicity assessment, a 3 × 3 matrix with variables defined in Table <a href="#pst70014-tbl-0001" class="usa-link">1</a> and depicted in Table <a href="#pst70014-tbl-0002" class="usa-link">2</a>. We set up simulation scenarios, ran each of them 1000 times, and sought statistically significant differences between the arms. Each scenario was run with a sample size of 600 patients for a total of 210 weeks to mirror large‐scale randomized trial parameters. Hazard ratios of 0.5, 1, and 2 are used for simplicity and reciprocal property.</p>
<p>Simulation of the 3 × 3 matrix for RBAs was performed for each of the five possible scenarios from each of the five possible cases of relative efficacy and toxicity: (i) more efficacy, same toxicity, (ii) same efficacy, less toxicity, (iii) more efficacy, less toxicity, (iv) more efficacy, more toxicity, and (v) same efficacy, same toxicity. In case (i), the experimental drug was more effective than the control drug [HR 0.5 for illness or death from disease progression] but equally toxic [HR 1.0 for illness or death from toxicity]. In case (ii), the experimental drug was equally effective as the control drug [HR 1.0] but was less toxic than the control drug [HR 0.5]. In case (iii), the experimental drug was both more effective [HR 0.5] and less toxic [HR 0.5] than the control drug. In case (iv), the experimental drug was more effective than the control drug [HR 0.5] but more toxic than the control drug [HR 2.0]. In case (v), the experimental drug was equally effective and equally toxic when compared to the control drug [HR 1.0 for both].</p></section><section id="pst70014-sec-0012"><h3 class="pmc_sec_title">2.5. Advanced Cancer Trial Simulation: 5 Efficacy × 6 Toxicity Matrix</h3>
<p>This simulation was built on the 6 stages of CTCAE toxicity and the five stages of RECIST 1.1 efficacy outlined in Table <a href="#pst70014-tbl-0003" class="usa-link">3</a>, as per standard methods in advanced cancer trials. This created the matrix shown in Table <a href="#pst70014-tbl-0004" class="usa-link">4</a>. As per our previous publications on using CWTA in cancer efficacy studies, all patients were assigned SD at time 0 and, each month, were capable of response (PR then CR), maintained SD, or irreversible exacerbation to PD or Death [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>, <a href="#pst70014-bib-0008" class="usa-link" aria-describedby="pst70014-bib-0008">8</a>]. We modeled a control group CR rate of ~10% and a PR rate of ~50% to reflect first‐line advanced cancer RCTs. Power was evaluated at increments of SS (20–320 patients in increments of 30) and HR (0.6, 0.7, and 0.8). The required sample size for (i) combined efficacy and toxicity as per Table <a href="#pst70014-tbl-0004" class="usa-link">4</a> and (ii) efficacy alone were directly compared.</p></section><section id="pst70014-sec-0013"><h3 class="pmc_sec_title">2.6. Statistical Analysis</h3>
<p>CWTA was performed as previously described [<a href="#pst70014-bib-0007" class="usa-link" aria-describedby="pst70014-bib-0007">7</a>] augmented by a cloud‐native cluster, with workloads executed in parallel across optimized Google Compute Engine virtual machines. For each trial, a <em>p</em>‐value was computed using CWTA (weighted logrank test). The fraction of tests that were significant (at <em>α</em> &lt; 0.05) represents the power of the test (correctly rejecting the null hypothesis that the two groups are the same). At each hazard ratio in our second model, a sample size requirement was interpolated as the threshold to reach 0.8 power, a common standard in RCT design.</p></section><section id="pst70014-sec-0014"><h3 class="pmc_sec_title">2.7. Real World Advanced Cancer Validation Study</h3>
<p>Our validation study was an analysis of real‐world data from a published dose escalation study in patients with advanced cancer. The PCLX‐001‐01 study evaluated escalating doses of continuous therapy with an oral anticancer drug, zelenirstat [<a href="#pst70014-bib-0020" class="usa-link" aria-describedby="pst70014-bib-0020">20</a>]. In this trial, 29 patients were assigned to various dose cohorts as shown in Table <a href="#pst70014-tbl-0005" class="usa-link">5</a>. Patients took zelenirstat until dose limiting toxicity was experienced or until progressive cancer was identified. Progressive cancer was identified by applying RECIST 1.1 criteria to CT scans performed every 2 months. Adverse events were logged for each day of study participation and defined and graded by CTCAE v5.0 criteria [<a href="#pst70014-bib-0010" class="usa-link" aria-describedby="pst70014-bib-0010">10</a>]. For this CWTA RBA, we restricted our analysis to symptomatic toxicities that developed on therapy (also known as treatment‐emergent toxicities) mapped to CTCAE v5.0. Due to the palliative nature of the population treated in this advanced cancer setting, we excluded asymptomatic laboratory abnormalities. Each day on therapy was assigned a highest‐grade symptomatic toxicity as per CTCAE criteria, and health states for each of the 29 subjects were assigned daily for each study day based on the 6 × 5 matrix as per Table <a href="#pst70014-tbl-0004" class="usa-link">4</a>.</p>
<section class="tw xbox font-sm" id="pst70014-tbl-0005"><h4 class="obj_head">TABLE 5.</h4>
<div class="caption p"><p>Dose‐escalation treatment cohorts in Pacylex zelenirstat phase I dose escalation clinical trial.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Dose level</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Zelenirstat (mg daily)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Number of subjects</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">RBA analysis vs. aggregated other cohorts</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">RBA weighted logrank analysis, <em>p</em> value</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">1</td>
<td align="center" valign="top" rowspan="1" colspan="1">20</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">Equivalent</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.913 (NS)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">2</td>
<td align="center" valign="top" rowspan="1" colspan="1">40</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">Equivalent</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.964 (NS)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">70</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">Worse</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.013 (significant)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">4</td>
<td align="center" valign="top" rowspan="1" colspan="1">100</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">Equivalent</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.406 (NS)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">140</td>
<td align="center" valign="top" rowspan="1" colspan="1">3</td>
<td align="center" valign="top" rowspan="1" colspan="1">Equivalent</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.933 (NS)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>6</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<strong>210</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<strong>7</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<strong>Better</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<strong>0.034 (significant)</strong>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">7</td>
<td align="center" valign="top" rowspan="1" colspan="1">280</td>
<td align="center" valign="top" rowspan="1" colspan="1">5</td>
<td align="center" valign="top" rowspan="1" colspan="1">Equivalent</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.553 (NS)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pst70014-tbl-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="pst70014-note-0002"><p>
<em>Note:</em> Using standard subjective assessment of toxicities and efficacy signals, dose level 6 had been selected by the clinical trialists and published as the recommended dose with which to conduct subsequent clinical trials (reference [<a href="#pst70014-bib-0006" class="usa-link" aria-describedby="pst70014-bib-0006">6</a>]). CWTA provides objective statistical validation for this decision.</p></div></div></section></section></section><section id="pst70014-sec-0015"><h2 class="pmc_sec_title">3. Results</h2>
<section id="pst70014-sec-0016"><h3 class="pmc_sec_title">3.1. Overview of Findings</h3>
<p>We first modeled the simplest possible state for combined efficacy and toxicity assessment, a 3 × 3 matrix. Simulation of the 3 × 3 matrix for CWTA RBAs confirmed all expectations for each of the five possible scenarios mapped to five possible combinations of relative efficacy and toxicity: (i) more efficacy, same toxicity, (ii) same efficacy, less toxicity, (iii) more efficacy, less toxicity, (iv) more efficacy, more toxicity, and (v) same efficacy, same toxicity. As expected and shown in Figure <a href="#pst70014-fig-0001" class="usa-link">1</a>, CWTA identified visually different and statistically significantly different (as assessed by weighted logrank testing) curves in cases (i) through (iv); curves were overlapping and the weighted logrank test was nonsignificant in cases (ii), (iv), and (v). The aggregate results of 1000‐fold simulations are shown in Figure <a href="#pst70014-fig-0002" class="usa-link">2</a>, in which only combination (iii), which synergized improved efficacy and lower toxicity, resulted in power beyond 0.8, the typical standard for trial design.</p>
<figure class="fig xbox font-sm" id="pst70014-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/660e/11975450/eabf850b1e8e/PST-24-0-g002.jpg" loading="lazy" id="jats-graphic-1" height="715" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/pst70014-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>3 × 3 simulation of combined efficacy and toxicity assessments. Each panel below shows a single representative trial from each of the five possible combinations of relative efficacy and toxicity: (i) more efficacy, same toxicity, (ii) same efficacy, less toxicity, (iii) more efficacy, less toxicity, (iv) more efficacy, more toxicity, and (v) same efficacy, same toxicity. Only trials (i) and (iii) demonstrated statistical significance at <em>α</em> = 0.05.</p></figcaption></figure><figure class="fig xbox font-sm" id="pst70014-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/660e/11975450/3b4bb6b0f852/PST-24-0-g001.jpg" loading="lazy" id="jats-graphic-3" height="421" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/pst70014-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>3 × 3 simulation overall comparison. Each horizontal bar represents the overall power of 1000‐fold simulated trials defined by five possible combinations of relative efficacy and toxicity: (i) more efficacy, same toxicity, (ii) same efficacy, less toxicity, (iii) more efficacy, less toxicity, (iv) more efficacy, more toxicity, and (v) same efficacy, same toxicity. Only case (iii), where improved efficacy synergized with lower toxicity, resulted in power beyond 0.8 (dashed vertical line), a usual standard for trial design.</p></figcaption></figure><p>Next, we modeled the case of an advanced cancer trial, in which efficacy signals were categorized as 5 possible ordinal variables as per RECIST 1.1 criteria, and toxicity was classified as per CTCAE 5.0 criteria in which there are six ordinal variables of toxicity. We conducted simulations of the 6 × 5 matrix RBA in Table <a href="#pst70014-tbl-0004" class="usa-link">4</a> across a range of hazard ratios favoring the experimental arm for both efficacy and toxicity (0.6, 0.7, and 0.8) and a range of sample sizes (20–320 patients in increments of 30). A single representative trial showing CWTA RBA vs. CWTA efficacy only is shown in Figure <a href="#pst70014-fig-0003" class="usa-link">3</a>, while overall results are shown in Figure <a href="#pst70014-fig-0004" class="usa-link">4</a>. These results show that RBA outperforms CWTA efficacy only analysis of studies when both efficacy and safety signals are favorable for the experimental drug. Sample sizes required to achieve 80% power were reduced by applying RBA, with larger reductions as hazard ratios approached 1.0; sample size reductions were 17% at a hazard ratio of 0.6 (RBA 44 patients vs. CWTA efficacy 53 patients), 18% at a hazard ratio of 0.7 (RBA 87 patients vs. CWTA efficacy 106 patients), and 24% reduction at a hazard ratio of 0.8 (RBA 212 patients vs. CWTA efficacy 279 patients). Sensitivity analysis (data not shown) confirmed that, as expected, improved efficacy can be offset by worsened toxicity in the experimental arm.</p>
<figure class="fig xbox font-sm" id="pst70014-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/660e/11975450/4d98fa60bcf9/PST-24-0-g003.jpg" loading="lazy" id="jats-graphic-5" height="1133" width="669" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/pst70014-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>6 toxicity × 5 efficacy matrix simulation comparing RBA vs. CWTA efficacy only. A single representative trial showing RBA vs. CWTA efficacy is shown here, where the efficacy HR was 0.8 and the toxicity HR was also at 0.8 for the experimental arm. Here, we see at a sample size of 200 subjects, RBA analysis was statistically significant, while the efficacy only CWTA analysis was negative. (i) CWTA efficacy only (<em>p</em> = 0.225). (ii) CWTA RBA (<em>p</em> = 0.014).</p></figcaption></figure><figure class="fig xbox font-sm" id="pst70014-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/660e/11975450/f9f7c1863b07/PST-24-0-g005.jpg" loading="lazy" id="jats-graphic-7" height="311" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/pst70014-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>6 toxicity × 5 efficacy matrix simulations: power as a function of sample size. We conducted simulations of the 6 × 5 matrix RBA across a range of hazard ratios favoring the experimental arm for both efficacy and toxicity (0.6, 0.7, and 0.8) and a range of sample sizes (20–320 patients in increments of 30) to compare CWTA RBA with CWTA efficacy‐alone analysis. Sample size reductions were 17% at a hazard ratio of 0.6 (RBA 44 patients vs. CWTA efficacy 53 patients), 18% at a hazard ratio of 0.7 (RBA 87 patients vs. CWTA efficacy 106 patients), and 24% reduction at a hazard ratio of 0.8 (RBA 212 patients vs. CWTA efficacy 279 patients).</p></figcaption></figure><p>Finally, we validated the 6 × 5 matrix CWTA RBA with real world data derived from a completed and published phase I dose escalation clinical trial in advanced cancer [<a href="#pst70014-bib-0020" class="usa-link" aria-describedby="pst70014-bib-0020">20</a>]. This phase I study involved evaluation of seven doses of a first‐in‐class small molecule inhibitor of N‐myristoylation, zelenirstat. In this dose escalation study, 29 patients were administered daily continuous oral zelenirstat at one of seven dose levels (Table <a href="#pst70014-tbl-0005" class="usa-link">5</a>). The trialists then used the standard toxicity assessment methods to define the Maximally Tolerated Dose (MTD) as first cycle Dose Limiting Toxicities (DLTs) occurring at a frequency of 33% or less, after which the efficacy signals were subjectively integrated into the decision to select dose level 6, 210 mg daily continuous therapy, as the recommended phase 2 dose for subsequent studies [<a href="#pst70014-bib-0012" class="usa-link" aria-describedby="pst70014-bib-0012">12</a>]. We applied the 6 × 5 CWTA RBA matrix to the completed zelenirstat trial database as shown in Figure <a href="#pst70014-fig-0005" class="usa-link">5</a>. These results confirmed that the recommended phase II dose, 210 mg daily, provided the statistically best combined health status for patients on that cohort, when compared with the aggregated health status of the patients treated on other cohorts, and was the only dose level to show significantly better outcomes. Thus, CWTA RBA objectively validated the investigator's subjective choice of cohort 6 as the recommended phase II dose.</p>
<figure class="fig xbox font-sm" id="pst70014-fig-0005"><h4 class="obj_head">FIGURE 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/660e/11975450/6df873ad9cc7/PST-24-0-g004.jpg" loading="lazy" id="jats-graphic-9" height="3037" width="664" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/pst70014-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Zelenirstat dose escalation RBA with 6 toxicity × 5 efficacy matrix analysis. Each panel below illustrates the RBA analysis of each cohort vs. the aggregated outcomes of all other cohorts. Patients in cohort 3 did significantly worse than other cohorts, while patients in cohort 6 had significantly better health status than patients in other cohorts. This result objectively validates the subjective assessment of the clinical trialists, who recommended proceeding with the 210 mg daily dose for subsequent clinical trials.</p></figcaption></figure></section></section><section id="pst70014-sec-0017"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Risk–benefit analysis (RBA) is an essential component of the development and evaluation of any health intervention. It is a complex assessment, representing the integration of efficacy/relative efficacy signals and safety/relative safety signals across the spectrum of clinical trials, regulatory reviews, and knowledge translation to clinical providers. We previously lacked a statistical tool that integrates both safety and efficacy signals, incorporates the trajectory of both disease and toxicity, yields a single test statistic, and readily communicates these outcomes visually.</p>
<p>In this study, we began with simulations of simplified therapeutic trials with three efficacy categories and three safety categories. We demonstrate that this model can produce composite CWTA analyses that accurately reflect the risk–benefit scenarios we modeled, across a range of therapeutic efficacy rates and toxicity rates (Figures <a href="#pst70014-fig-0001" class="usa-link">1</a> and <a href="#pst70014-fig-0002" class="usa-link">2</a>). These results confirmed the intuitive assumptions that CWTA could correctly identify an experimental drug that had better efficacy than the control drug, better toxicity than the control drug, or both better efficacy and toxicity. As expected, more effective but more toxic drugs did not show improved CWTA RBA.</p>
<p>Next, we simulated the more complex scenario of an advanced cancer therapy trial, in which efficacy status was captured with five categories (CR, PR, SD, PD, and Death), and key toxicities were captured with CTCAE v5.0 categorized toxicities ranging from grade 0 (no toxicity) to grade 5 (fatal). In this simulation, efficacy was assessed monthly, while adverse events were modeled with weekly changes, reflecting the real‐world complexities of an advanced cancer trial. We demonstrated that across a range of clinically relevant efficacy rates, as identified by hazard ratios compared to control therapies, and various assumptions of toxicity rates, CWTA could address these complexities and distill the risk–benefit assessment into a relatively simple single metric and single visualization. Importantly, CWTA RBA was more powerful than CWTA efficacy alone, requiring fewer patients to demonstrate superiority of a drug that is both more effective and less toxic. Given that CWTA efficacy analyses already are substantially more effective than standard Kaplan–Meier analyses of Progression Free Survival and Overall Survival in the settings of advanced cancer [<a href="#pst70014-bib-0008" class="usa-link" aria-describedby="pst70014-bib-0008">8</a>], this demonstrates that CWTA RBA permits markedly smaller sample sizes than standard KM endpoints in advanced cancer, further reducing subject numbers, time to completion of study, and trial costs.</p>
<p>Finally, we applied CWTA to a real‐world clinical trial dataset derived from a dose escalation trial using the first in class agent, zelenirstat. While this drug had not previously been studied in humans, pre‐clinical toxicities were primarily those of gastrointestinal events. As such, a pre‐specified list of adverse events of special interest (AEIs) and a selection of dose limiting toxicities were assigned prior to launching the study. As the cancer population was treatment refractory, with a median of four prior courses of systemic therapy (ranging up to 8), the population was not healthy and had baseline symptoms including fatigue, neuropathy, and others. Despite the complexities of the trial population and the small number of patients in each cohort, CWTA RBA clearly demonstrated its utility in this complex setting, correctly identifying the go‐forward dose derived from the standard, subjective analysis of the study. That CWTA achieved statistical significance when the RPD2 cohort (<em>n</em> = 7) was compared to non‐RPD2 cohort patients (<em>n</em> = 22) was a striking validation of the power of CWTA RBA in the analysis of trials with small sample sizes.</p>
<p>Our findings are particularly relevant in the context of regulatory efforts to improve dose and schedule optimization in the context of clinical trials. The US FDA's Project Optimus is an initiative by the Oncology Center of Excellence aimed at reforming the dose optimization and dose selection paradigm in oncology drug development [<a href="#pst70014-bib-0021" class="usa-link" aria-describedby="pst70014-bib-0021">21</a>, <a href="#pst70014-bib-0022" class="usa-link" aria-describedby="pst70014-bib-0022">22</a>, <a href="#pst70014-bib-0023" class="usa-link" aria-describedby="pst70014-bib-0023">23</a>]. Traditionally, dosages for oncology drugs were selected based on the maximum tolerated dose (MTD), which may lead to severe toxicities without additional efficacy benefits. Project Optimus seeks to address this by encouraging early and rigorous dose‐finding studies that balance efficacy and safety, minimizing long‐term toxicities and improving patient outcomes. CWTA, applied to this effort, would provide statistical rigor and objective criteria on which the optimal dose and schedule of cancer drugs are based.</p>
<p>Effectively communicating the risks and benefits to participants in clinical trials, healthcare professionals, and the public is critical and challenging. Miscommunication can lead to misunderstandings about the safety and efficacy of a drug, impacting patient trust and the overall perception of the drug's value. Currently, communicating clinical benefit and clinical toxicity is difficult, due in part to the lack of methods to integrate both into a single, easily explained metric. For example, the dramatic efficacy of COVID‐19 vaccines in reducing hospitalization and death was, in public communications, largely disassociated from the potential for rare, albeit serious, adverse effects [<a href="#pst70014-bib-0024" class="usa-link" aria-describedby="pst70014-bib-0024">24</a>]. In principle, using CWTA to integrate both efficacy (freedom from hospitalization, ICU, and death) and key safety considerations with serious adverse events (acute vaccine reactions, myocarditis, Guillain Barre syndrome) could provide a single, easily explained, readily visualized difference in health status between a vaccinated and unvaccinated population.</p>
<p>Our methodology is distinct from decision analytic models, which are mathematical tools used to aid decision‐making in situations of uncertainty. Such models help evaluate different decision paths based on their potential outcomes and the probabilities of these outcomes. In particular, Bayesian trials can be structured to assess both safety and efficacy endpoints simultaneously. This is achieved by defining prior probabilities for both the efficacy and safety of the intervention and then updating these probabilities as data on these endpoints are collected throughout the trial. However, CWTA, unlike Bayesian trials, can give time‐dependent toxicity assessments that recover, unlike the typical Bayesian design where toxicities of a certain severity (typically grade 3 or higher) are tallied as discrete isolated incidents, irrespective of their duration. Consequently, CWTA gives a more nuanced and accurate reflection of the patient experience, particularly in settings of transient toxicities which are either self‐limited or responsive to therapy. Furthermore, full Bayesian risk–benefit analyses are difficult to communicate and are not reducible to a single test statistic and a simple graphic representation.</p>
<p>In the absence of defined or known key toxicities, such as in the early‐stage trial setting, CWTA can be structured to assess efficacy signals in tandem with any toxicities, as we did here with the zelenirstat study, agnostic to the specifics of the toxicity experienced by the study subjects. However, CWTA can be customized to address RBA in the context of phase II trials and beyond, where the key toxicities of the intervention are known prior to study inception. In such a setting, adverse events of special interest could be prospectively incorporated into a study‐specific ordinal outcome matrix that ranks the clinical importance of the toxicities, relating them to the clinical importance of efficacy metrics, to generate a combined ordinal ranking that can be used as the primary CWTA RBA endpoint throughout the trial.</p>
<p>Our study has limitations. We specifically addressed the context of advanced cancer trials in our second simulation model and our real‐world analysis, in which CTCAE adverse events were integrated into cancer efficacy endpoints. In principle, our findings are expected to be generalizable to other efficacy scales and other toxicity scales, as the improved power of the methodology comes from the incorporation of the full dataset in the analyses. We have, however, not explored other matrices which might be more relevant to nononcology studies. We suspect that the methodology and learnings from this study are generally applicable to medical device trials, public health interventions, and industrial applications, and these will be areas for further research.</p>
<p>Finally, CWTA RBA benefits from very granular data on timing, severity, and resolution of toxicity data; while these data are captured in case report forms, some additional programming is required to extract the trajectory of all adverse events, rather than the usual reporting of rates of individuals with high‐grade toxicities.</p></section><section id="pst70014-sec-0018"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>CWTA RBA, by incorporating the efficacy and toxicity signals throughout the entirety of the health trajectory of trial participants, provides a single statistic and summary plot that analyzes and effectively communicates the risks and benefits of a clinical trial intervention. CWTA RBA can be fruitfully applied even to small phase I studies, and can provide objective evaluations at any point in a study and across the spectrum of clinical trials of new therapeutics. Our data confirm that using CWTA RBA could aid the assessment of new therapies at multiple levels, including the design phase of clinical trials, interim analyses, adaptive design assessment of alternative therapies, regulatory review, and clinical adoption and communication of therapeutic benefit to clinicians, patients, and funders. We propose CWTA as a flexible and pragmatic tool for aggregate assessment of risk–benefit in the development and comparative assessment of health interventions.</p></section><section id="pst70014-sec-0020"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>U.C. and D.M. have leadership roles and stock in CW Trial Analytics.</p></section><section id="pst70014-sec-0019" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We thank Pacylex Pharmaceuticals Inc. for sharing their data on trial PCLX‐001‐01/<a href="https://clinicaltrials.gov/ct2/show/NCT04836195" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04836195</a> for the analyses in this paper.</p></section><section id="pst70014-sec-0022"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section><section id="pst70014-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="pst70014-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="pst70014-bib-0001">
<span class="label">1.</span><cite>
U.S. Food and Drug Administration
, Benefit‐Risk Assessment for New Drug and Biological Products n.d. accessed July 25, 2024, <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/benefit‐risk‐assessment‐new‐drug‐and‐biological‐products</a>.</cite>
</li>
<li id="pst70014-bib-0002">
<span class="label">2.</span><cite>
Hughes D., Waddingham E., Mt‐Isa S., et al., “Recommendations for Benefit–Risk Assessment Methodologies and Visual Representations,” Pharmacoepidemiology and Drug Safety
25, no. 3 (2016): 251–262, 10.1002/pds.3958.
</cite> [<a href="https://doi.org/10.1002/pds.3958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26800458/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacoepidemiology%20and%20Drug%20Safety&amp;title=Recommendations%20for%20Benefit%E2%80%93Risk%20Assessment%20Methodologies%20and%20Visual%20Representations&amp;author=D.%20Hughes&amp;author=E.%20Waddingham&amp;author=S.%20Mt%E2%80%90Isa&amp;volume=25&amp;issue=3&amp;publication_year=2016&amp;pages=251-262&amp;pmid=26800458&amp;doi=10.1002/pds.3958&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0003">
<span class="label">3.</span><cite>
van der Worp H. B., Howells D. W., Sena E. S., et al., “Can Animal Models of Disease Reliably Inform Human Studies?,” PLoS Medicine
7, no. 3 (2010): e1000245, 10.1371/journal.pmed.1000245.
</cite> [<a href="https://doi.org/10.1371/journal.pmed.1000245" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2846855/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20361020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Medicine&amp;title=Can%20Animal%20Models%20of%20Disease%20Reliably%20Inform%20Human%20Studies?&amp;author=H.%20B.%20van%20der%20Worp&amp;author=D.%20W.%20Howells&amp;author=E.%20S.%20Sena&amp;volume=7&amp;issue=3&amp;publication_year=2010&amp;pages=e1000245&amp;pmid=20361020&amp;doi=10.1371/journal.pmed.1000245&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0004">
<span class="label">4.</span><cite>
Ferreira G. S., Veening‐Griffioen D. H., Boon W. P. C., Moors E. H. M., and Gispen‐de Wied C. C., “A Standardised Framework to Identify Optimal Animal Models for Efficacy Assessment in Drug Development,” PLoS One
14, no. 7 (2019): e0220325, 10.1371/journal.pone.0220325.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0220325" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6563989/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31194784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=A%20Standardised%20Framework%20to%20Identify%20Optimal%20Animal%20Models%20for%20Efficacy%20Assessment%20in%20Drug%20Development&amp;author=G.%20S.%20Ferreira&amp;author=D.%20H.%20Veening%E2%80%90Griffioen&amp;author=W.%20P.%20C.%20Boon&amp;author=E.%20H.%20M.%20Moors&amp;author=C.%20C.%20Gispen%E2%80%90de%20Wied&amp;volume=14&amp;issue=7&amp;publication_year=2019&amp;pages=e0220325&amp;pmid=31194784&amp;doi=10.1371/journal.pone.0220325&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0005">
<span class="label">5.</span><cite>
Kaplan E. L. and Meier P., “Nonparametric Estimation From Incomplete Observations,” Journal of the American Statistical Association
53 (1958): 457–481, 10.1080/01621459.1958.10501452.</cite> [<a href="https://doi.org/10.1080/01621459.1958.10501452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20American%20Statistical%20Association&amp;title=Nonparametric%20Estimation%20From%20Incomplete%20Observations&amp;author=E.%20L.%20Kaplan&amp;author=P.%20Meier&amp;volume=53&amp;publication_year=1958&amp;pages=457-481&amp;doi=10.1080/01621459.1958.10501452&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0006">
<span class="label">6.</span><cite>
Peto R., Pike M., Armitage P., et al., “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient. I. Introduction and Design,” British Journal of Cancer
34 (1976): 585–612, 10.1038/bjc.1976.220.
</cite> [<a href="https://doi.org/10.1038/bjc.1976.220" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2025229/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/795448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Design%20and%20Analysis%20of%20Randomized%20Clinical%20Trials%20Requiring%20Prolonged%20Observation%20of%20Each%20Patient.%20I.%20Introduction%20and%20Design&amp;author=R.%20Peto&amp;author=M.%20Pike&amp;author=P.%20Armitage&amp;volume=34&amp;publication_year=1976&amp;pages=585-612&amp;pmid=795448&amp;doi=10.1038/bjc.1976.220&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0007">
<span class="label">7.</span><cite>
Chauhan U., Zhao K., Walker J., and Mackey J. R., “Weighted Trajectory Analysis and Application to Clinical Outcome Assessment,” BioMedInformatics
3 (2023): 829–852, 10.3390/biomedinformatics3040052.</cite> [<a href="https://doi.org/10.3390/biomedinformatics3040052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BioMedInformatics&amp;title=Weighted%20Trajectory%20Analysis%20and%20Application%20to%20Clinical%20Outcome%20Assessment&amp;author=U.%20Chauhan&amp;author=K.%20Zhao&amp;author=J.%20Walker&amp;author=J.%20R.%20Mackey&amp;volume=3&amp;publication_year=2023&amp;pages=829-852&amp;doi=10.3390/biomedinformatics3040052&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0008">
<span class="label">8.</span><cite>
Chauhan U., Mackey D., and Mackey J. R., “Chauhan Weighted Trajectory Analysis Reduces Sample Size Requirements and Expedites Time‐To‐Efficacy Signals in Advanced Cancer Clinical Trials,” BioMedInformatics
4 (2024): 1703–1712, 10.3390/biomedinformatics4030092.</cite> [<a href="https://doi.org/10.3390/biomedinformatics4030092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BioMedInformatics&amp;title=Chauhan%20Weighted%20Trajectory%20Analysis%20Reduces%20Sample%20Size%20Requirements%20and%20Expedites%20Time%E2%80%90To%E2%80%90Efficacy%20Signals%20in%20Advanced%20Cancer%20Clinical%20Trials&amp;author=U.%20Chauhan&amp;author=D.%20Mackey&amp;author=J.%20R.%20Mackey&amp;volume=4&amp;publication_year=2024&amp;pages=1703-1712&amp;doi=10.3390/biomedinformatics4030092&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0009">
<span class="label">9.</span><cite>
Eisenhauer E. A., Therasse P., Bogaerts J., et al., “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer
45, no. 2 (2009): 228–247.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2008.10.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=New%20Response%20Evaluation%20Criteria%20in%20Solid%20Tumours:%20Revised%20RECIST%20Guideline%20(Version%201.1)&amp;author=E.%20A.%20Eisenhauer&amp;author=P.%20Therasse&amp;author=J.%20Bogaerts&amp;volume=45&amp;issue=2&amp;publication_year=2009&amp;pages=228-247&amp;pmid=19097774&amp;doi=10.1016/j.ejca.2008.10.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0010">
<span class="label">10.</span><cite>
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (U.S. Department of Health and Human Services, 2017), accessed, <a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Common%20Terminology%20Criteria%20for%20Adverse%20Events%20(CTCAE)%20Version%205.0&amp;publication_year=2017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0011">
<span class="label">11.</span><cite>
Aalen O., “Nonparametric Inference for a Family of Counting Processes,” Annals of Statistics
6 (1978): 701–726, 10.1214/aos/1176344136.</cite> [<a href="https://doi.org/10.1214/aos/1176344136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Statistics&amp;title=Nonparametric%20Inference%20for%20a%20Family%20of%20Counting%20Processes&amp;author=O.%20Aalen&amp;volume=6&amp;publication_year=1978&amp;pages=701-726&amp;doi=10.1214/aos/1176344136&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0012">
<span class="label">12.</span><cite>
Fleming T. R. and Harrington D. P., “A Class of Hypothesis Tests for One‐ and Two‐Sample Censored Survival Data,” Communications in Statistics ‐ Theory and Methods
10, no. 8 (1981): 763–794, 10.1080/03610928108828102.</cite> [<a href="https://doi.org/10.1080/03610928108828102" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Communications%20in%20Statistics%20%E2%80%90%20Theory%20and%20Methods&amp;title=A%20Class%20of%20Hypothesis%20Tests%20for%20One%E2%80%90%20and%20Two%E2%80%90Sample%20Censored%20Survival%20Data&amp;author=T.%20R.%20Fleming&amp;author=D.%20P.%20Harrington&amp;volume=10&amp;issue=8&amp;publication_year=1981&amp;pages=763-794&amp;doi=10.1080/03610928108828102&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0013">
<span class="label">13.</span><cite>
Wei L. J., Lin D. Y., and Weissfeld L., “Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions,” Journal of the American Statistical Association
84 (1989): 1065–1073, 10.1080/01621459.1989.10478873.</cite> [<a href="https://doi.org/10.1080/01621459.1989.10478873" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20American%20Statistical%20Association&amp;title=Regression%20Analysis%20of%20Multivariate%20Incomplete%20Failure%20Time%20Data%20by%20Modeling%20Marginal%20Distributions&amp;author=L.%20J.%20Wei&amp;author=D.%20Y.%20Lin&amp;author=L.%20Weissfeld&amp;volume=84&amp;publication_year=1989&amp;pages=1065-1073&amp;doi=10.1080/01621459.1989.10478873&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0014">
<span class="label">14.</span><cite>
Liang K. Y. and Zeger S. L., “Longitudinal Data Analysis Using Generalized Linear Models,” Biometrika
73 (1986): 13–22, 10.1093/biomet/73.1.13.</cite> [<a href="https://doi.org/10.1093/biomet/73.1.13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biometrika&amp;title=Longitudinal%20Data%20Analysis%20Using%20Generalized%20Linear%20Models&amp;author=K.%20Y.%20Liang&amp;author=S.%20L.%20Zeger&amp;volume=73&amp;publication_year=1986&amp;pages=13-22&amp;doi=10.1093/biomet/73.1.13&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0015">
<span class="label">15.</span><cite>
Lumley T., “Generalized Estimating Equations for Ordinal Data: A Note on Working Correlation Structures,” Biometrics
52 (1996): 354–361, 10.2307/2533167.
</cite> [<a href="https://doi.org/10.2307/2533167" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8934602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biometrics&amp;title=Generalized%20Estimating%20Equations%20for%20Ordinal%20Data:%20A%20Note%20on%20Working%20Correlation%20Structures&amp;author=T.%20Lumley&amp;volume=52&amp;publication_year=1996&amp;pages=354-361&amp;pmid=8934602&amp;doi=10.2307/2533167&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0016">
<span class="label">16.</span><cite>
Andersen P. K. and Keiding N., “Multi‐State Models for Event History Analysis,” Statistical Methods in Medical Research
11 (2002): 91–115, 10.1191/0962280202sm276ra.
</cite> [<a href="https://doi.org/10.1191/0962280202sm276ra" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12040698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Statistical%20Methods%20in%20Medical%20Research&amp;title=Multi%E2%80%90State%20Models%20for%20Event%20History%20Analysis&amp;author=P.%20K.%20Andersen&amp;author=N.%20Keiding&amp;volume=11&amp;publication_year=2002&amp;pages=91-115&amp;pmid=12040698&amp;doi=10.1191/0962280202sm276ra&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0017">
<span class="label">17.</span><cite>
Le‐Rademacher J., Moreira J., Sohn M., et al., “Statistical Considerations in Clinical Trials of Cancer Therapies,” Clinical Trials
15, no. 5 (2018): 467–475, 10.1177/1740774518789098.</cite> [<a href="https://doi.org/10.1177/1740774518789098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Trials&amp;title=Statistical%20Considerations%20in%20Clinical%20Trials%20of%20Cancer%20Therapies&amp;author=J.%20Le%E2%80%90Rademacher&amp;author=J.%20Moreira&amp;author=M.%20Sohn&amp;volume=15&amp;issue=5&amp;publication_year=2018&amp;pages=467-475&amp;doi=10.1177/1740774518789098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0018">
<span class="label">18.</span><cite>
Python Software Foundation
, Python Language Reference, Version 3.8 (Python Software Foundation, 2024), accessed July 25, 2024, <a href="http://www.python.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.python.org</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Python%20Language%20Reference,%20Version%203.8&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0019">
<span class="label">19.</span><cite>
National Cancer Institute, SEER Cancer Statistics Review, 1975–2021 (National Cancer Institute, 2023), <a href="https://seer.cancer.gov" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://seer.cancer.gov</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=SEER%20Cancer%20Statistics%20Review,%201975%E2%80%932021&amp;publication_year=2023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0020">
<span class="label">20.</span><cite>
Sangha R., Jamal R., Spratlin J., et al., “A First‐In‐Human Phase I Trial of Daily Oral Zelenirstat, a N‐Myristoyltransferase Inhibitor, in Patients With Advanced Solid Tumors and Relapsed/Refractory B‐Cell Lymphomas,” Investigational New Drugs
42 (2024): 386–393, 10.1007/s10637-024-01448-w.
</cite> [<a href="https://doi.org/10.1007/s10637-024-01448-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11327210/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38837078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Investigational%20New%20Drugs&amp;title=A%20First%E2%80%90In%E2%80%90Human%20Phase%20I%20Trial%20of%20Daily%20Oral%20Zelenirstat,%20a%20N%E2%80%90Myristoyltransferase%20Inhibitor,%20in%20Patients%20With%20Advanced%20Solid%20Tumors%20and%20Relapsed/Refractory%20B%E2%80%90Cell%20Lymphomas&amp;author=R.%20Sangha&amp;author=R.%20Jamal&amp;author=J.%20Spratlin&amp;volume=42&amp;publication_year=2024&amp;pages=386-393&amp;pmid=38837078&amp;doi=10.1007/s10637-024-01448-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0021">
<span class="label">21.</span><cite>
U.S. Food and Drug Administration
, FDA Project Optimus accessed July 25, 2024, <a href="https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/about‐fda/oncology‐center‐excellence/project‐optimus</a>.</cite>
</li>
<li id="pst70014-bib-0022">
<span class="label">22.</span><cite>
Fourie Zirkelbach J., Shah M., Vallejo J., et al., “Improving Dose‐Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients,” Journal of Clinical Oncology
40, no. 30 (2022): 3489–3500, 10.1200/JCO.2200371.
</cite> [<a href="https://doi.org/10.1200/JCO.2200371" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36095296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Improving%20Dose%E2%80%90Optimization%20Processes%20Used%20in%20Oncology%20Drug%20Development%20to%20Minimize%20Toxicity%20and%20Maximize%20Benefit%20to%20Patients&amp;author=J.%20Fourie%20Zirkelbach&amp;author=M.%20Shah&amp;author=J.%20Vallejo&amp;volume=40&amp;issue=30&amp;publication_year=2022&amp;pages=3489-3500&amp;pmid=36095296&amp;doi=10.1200/JCO.2200371&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0023">
<span class="label">23.</span><cite>
Schmid P., Cruz C., Wolff A. C., et al., “Optimizing the Safety of Antibody–Drug Conjugates for Patients With Solid Tumours,” Nature Reviews. Clinical Oncology
21 (2024): 141–155, 10.1038/s41571-023-00853-z.</cite> [<a href="https://doi.org/10.1038/s41571-023-00853-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37296177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Clinical%20Oncology&amp;title=Optimizing%20the%20Safety%20of%20Antibody%E2%80%93Drug%20Conjugates%20for%20Patients%20With%20Solid%20Tumours&amp;author=P.%20Schmid&amp;author=C.%20Cruz&amp;author=A.%20C.%20Wolff&amp;volume=21&amp;publication_year=2024&amp;pages=141-155&amp;pmid=37296177&amp;doi=10.1038/s41571-023-00853-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pst70014-bib-0024">
<span class="label">24.</span><cite>
Razai M. S., Chaudhry U. A. R., Doerholt K., Bauld L., and Majeed A., “Covid‐19 Vaccination Hesitancy,” BMJ
373 (2021): n1138, 10.1136/bmj.n1138.
</cite> [<a href="https://doi.org/10.1136/bmj.n1138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34016653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Covid%E2%80%9019%20Vaccination%20Hesitancy&amp;author=M.%20S.%20Razai&amp;author=U.%20A.%20R.%20Chaudhry&amp;author=K.%20Doerholt&amp;author=L.%20Bauld&amp;author=A.%20Majeed&amp;volume=373&amp;publication_year=2021&amp;pages=n1138&amp;pmid=34016653&amp;doi=10.1136/bmj.n1138&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Pharmaceutical Statistics are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/pst.70014"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/PST-24-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11975450/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11975450/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11975450%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11975450/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11975450/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11975450/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40194510/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11975450/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40194510/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11975450/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11975450/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="4s3iu0te2Ig2Dwv8RgTD3Y2chz1XtK3dSYt3IBmKZgcITDYkOOIM6tO1CONMRcZ4">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
